Bench Side Story continues with Dr Kelsie Raspin, a dedicated Postdoctoral Research Fellow specialising in Cancer Genetics at Menzies Institute for Medical Research, University of Tasmania, AUSTRALIA
Her primary research focus revolves around bridging a critical knowledge gap in the understanding of genetic alterations implicated in prostate cancer initiation and its progression into metastatic forms.
Driven by an unwavering commitment to equitable access to genomic innovation in clinical cancer care, Kelsie aspires to enhance health outcomes not only for her fellow Tasmanians but also for individuals worldwide.
Kelsie’s research is funded through an RHH Research Foundation grant.
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
-
Tyrosine Kinases in cancer recurrence
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
